drugset / Trial / NCT01604265

A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis

NCT01604265

Phase 3 Completed 66 enrolled Jazz Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To investigate the ability of Sativex to relieve central neuropathic pain in multiple sclerosis subjects.

Timeline

Start
2002-03
Primary completion
2002-08
Completion
2002-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Nabiximols Other / unclassified 2.5 mg Other